Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer

Mikihiro Kusama,Tadashi Nomizu,Kenjiro Aogi,Masataka Yoshimoto,Horikoshi N,Toshio Tabei,Shinzaburo Noguchi,Shigeto Miura,N Yoshimura,Morihiko Kimura,Kazushige Toyama,Eisei Shin

Phase II study of 4-weekly capecitabine monotherapy in advanced/metastatic breast cancer

2010

Mikihiro Kusama
Tadashi Nomizu
Kenjiro Aogi
Masataka Yoshimoto
Horikoshi N
Toshio Tabei
Shinzaburo Noguchi
Shigeto Miura
N Yoshimura
Morihiko Kimura
Kazushige Toyama
Eisei Shin

Background A multicenter, phase II study was conducted to evaluate the efficacy and safety of the Japanese intermittent 4-week regimen of capecitabine in patients with advanced/metastatic breast cancer.

Keywords:

Breast cancer
Capecitabine
Stable Disease
Phases of clinical research
Confidence interval
Regimen
Metastatic breast cancer
Medicine
Internal medicine
Adverse effect
Oncology
in patient
Surgical oncology

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations